Syros Pharmaceuticals (SYRS)
(Real Time Quote from BATS)
$5.00 USD
0.00 (0.00%)
Updated May 29, 2024 02:10 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Syros Pharmaceuticals, Inc. [SYRS]
Reports for Purchase
Showing records 21 - 40 ( 221 total )
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
SY-5609 Continues to Garner Investor Interest, While Pipeline Remains on Track; Reit Buy and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q21 Updates - Steady as She Goes, Making Headway Across Its Pipeline
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
First Patient Dosed with SY-2101 in APL Dose Conf. Study - Data in 1H2022
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Large Pharma Veteran, Conley Chee,Appointed as CCO
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Early Data & Development Strategy for SY-5609 Supports Raising PT to $23
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Syros Will Explore Combination Strategies For SY-5609 Moving Forward
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Optimal Dosing Regimen for SY-5609 Likely Found - More at ESMO on Monday
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Mark Your Calendars for SY-5609''s ESMO Data & Follow-Up Call on Sep. 20th
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q21 Updates - Heme Franchise Advances While Roche Spotlights SY-5609
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Roche Agreement Shines Light on Oral CDK7 Asset; Reit Buy and $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
KOL Series on Heme Franchise Wraps Up With SY-2101''s Opportunity in APL
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Syros Hosts KOL Event Highlighting the Unmet Medical Need in APL
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A